Pregabalin was associated with an increased risk for heart failure relative to another widely used gabapentinoid, based on an ...

The designation was based on the therapy’s novel mechanism and data showing its anti-tumour activity in B-cell malignancies.

(NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2025. "In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine ...

Investing.com -- 4D Molecular Therapeutics (NASDAQ: FDMT) stock rose 36% after the company announced positive 60-week results from its 4D-150 SPECTRA clinical trial in diabetic macular edema (DME) and ...

Warning as softgel capsule supplements linked to range of health concerns - The smooth, easy-to-swallow capsules have come ...

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some success ...

D Molecular Therapeutics has posted 60-week data on a gene therapy, providing evidence of durability in diabetic macular edema and sending its stock up more than 40% in premarket trading.

Ocugen has scheduled a conference call and webcast for 8:30 a.m. ET today to discuss the financial results and recent business highlights. Ocugen’s executive leadership team will host the call, which ...

Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United ...

Swadeshi Jagran Manch advocates for waiving animal trials in biosimilar approval process to make drugs more affordable and ...

KBC notes the announcements made today by the European Banking Authority (EBA) regarding the results of the 2025 EU-wide stress test. A brief set of slides on the KBC data is available at Under the ...

This past year has seen various developments in the field of oncolytic virus therapies - in fundraising and in the clinic.